(TheNewswire)
LONDON, ONTARIO – TheNewswire - May 4, 2021 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE/XETRA:PSH ), a leading clinical-stageregenerative medicine therapeutics company, today announced thatseasoned pharmaceutical industry executive, Dr. Mohammad Azab, MB ChB,MSc, MBA, has been nominated by the Company to its Board of Directors.
“Dr. Azab’s extensive knowledge and experience inthe pharmaceutical industry, as well as his many industry connections,make him an excellent fit for the Board of Sernova, particularly asthe Company expands its clinical development programs for thetreatment of chronic diseases such as diabetes, thyroid and rarediseases,” said Frank Holler, Chairman of the Board of Sernova.“Dr. Azab’s appointment further supports the Company’s near-termgoal to bolster its Board of Directors, as well as Scientific Advisoryand Global Advisory Boards, in line with our expanding research,development and business activities.”
Dr. Azab served as President and Chief Medical Officerof Astex Pharmaceuticals, Inc., a pharmaceutical company focused onthe discovery and development of drugs in oncology and other diseaseindications. As of November 2020, upon retirement from his managementrole, Dr. Azab has served as the Chair of the Board of Directors forAstex Pharmaceuticals, Inc, which is now a wholly-owned subsidiary ofOtsuka Pharmaceuticals. Previously, Dr. Azab served as President andCEO of Intradigm Corporation, a developer of siRNA cancertherapeutics. Prior to this, Dr. Azab served as Executive VicePresident of Research and Development and Chief Medical Officer of QLTInc., and in several leadership positions at AstraZeneca in the UnitedKingdom and Sanofi Pharmaceuticals in France. Dr. Azab holds hismedical degree (MB ChB) from Cairo University and an MBA from theRichard Ivey School of Business, Western University, Ontario. Hereceived post-graduate training and degrees in oncology research fromthe University of Paris-Sud and biostatistics from the University ofPierre et Marie Curie in Paris, France.
“I am excited to be nominated to join Sernova’sBoard of Directors,” said Dr. Mohammad Azab. “I intend to bring myexperience and additional perspectives to support Sernova and itsmanagement team as the company progresses it novel regenerativemedicine therapeutic programs with the aim to provide a ‘functionalcure’ for patients suffering from chronic diseases.”
Dr. Azab has more than 30 years of experience inclinical research, business management and led the global developmentof several drugs currently approved in oncology and other therapeuticareas. Currently, he also serves on the board of directors of NASDAQlisted companies, Xenon Pharmaceuticals Inc. (XENE), and DurectCorporation (DRRX).
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologiesusing its Cell Pouch medical device, therapeutic cells (i.e., humandonor cells, corrected human cells, stem cell-derived cells andtissues) and immune protection technologies to improve the treatmentand quality of life of people living with chronic metabolic diseasessuch as insulin-dependent diabetes, blood disorders includinghemophilia, and other diseases treated through replacement of proteinsor hormones missing or in short supply within the body. For moreinformation, please visit www.sernova.com .
FOR FURTHER INFORMATION, PLEASECONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-lookingstatements are statements that are not historical facts and aregenerally, but not always, identified by the words"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential" and similar expressions,or that events or conditions "will", "would","may", "could" or "should" occur.Although Sernova believes the expectations expressed in suchforward-looking statements are based on reasonable assumptions, suchstatements are not guarantees of future performance, and actualresults may differ materially from those in forward-lookingstatements. Forward-looking statements are based on the beliefs,estimates, and opinions of Sernova’s management on the date suchstatements were made, which include our beliefs about the conduct andoutcome of clinical trials. Sernova expressly disclaims any intentionor obligation to update or revise any forward-looking statementswhether as a result of new information, future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.